Following the recent decision by a US District Court judge in which EliLilly lost patent protection for the antidepressant Prozac (fluoxetine; Marketletter August 6), Israel's Teva Pharmaceuticals has become the most recent of several drugmakers to have received clearance from the US Food and Drug Administration to market generic versions of the drug.
Teva received FDA approval for fluoxetine oral solution (20mg per 5ml) last week and expects to launch the drug immediately. It received a 180-day period of market exclusivity for this formulation, which follows the previously-gained tentative approval from the FDA for 10mg fluoxetine tablets (Marketletter June 11).
Companies now shipping fluoxetine
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze